Premium
[RuCl 3 ind 3 ] and [RuCl 2 ind 4 ]: Two New Ruthenium Complexes derived from the Tumor‐inhibiting Ru III Compound HInd ( OC ‐6‐11)‐[RuCl 4 ind 2 ] (ind = indazole)
Author(s) -
Pieper Thomas,
Sommer Martina,
Galanski Mathea Sophia,
Keppler Bernhard K.,
Giester Gerald
Publication year - 2001
Publication title -
zeitschrift für anorganische und allgemeine chemie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.354
H-Index - 66
eISSN - 1521-3749
pISSN - 0044-2313
DOI - 10.1002/1521-3749(200102)627:2<261::aid-zaac261>3.0.co;2-k
Subject(s) - ruthenium , monoclinic crystal system , chemistry , indazole , tetrahydrofuran , crystallography , stereochemistry , crystal structure , organic chemistry , catalysis , solvent
Indazolium ( OC ‐6‐11)‐tetrachlorobis(indazole) ruthenate(III), HInd ( OC ‐6‐11)‐[RuCl 4 ind 2 ], exhibits excellent results in different tumor models in vitro and in vivo . Substitution reactions of this ruthenium(III) complex are of special interest for a deeper understanding of its interactions with biologically occurring targets and its mode of action. The indazolium complex salt can be transformed to the neutral, meridionally configurated trisindazole complex ( OC ‐6‐21)‐[RuCl 3 ind 3 ] in solvents like tetrahydrofuran. The X‐ray crystal structure of this complex could be solved (monoclinic space group P2(1)/n, a = 12.441(3), b = 10.415(3), c = 21.635(4) Å, β = 105.02(1)°). In spite of the paramagnetic Ru III atom most of the coordinated indazole protons could be assigned with the help of two‐dimensional NMR experiments. Additionally, a reduced reaction product of HInd ( OC ‐6‐11)‐[RuCl 4 ind 2 ] in the physiological solubilizer 2‐pyrrolidone could be isolated and the X‐ray crystal structure of this Ru II complex, ( OC ‐6‐12)‐[RuCl 2 ind 4 ], crystallized with two 2‐pyrrolidones, could be solved (monoclinic space group P2(1)/n, a = 12.139(2), b = 10.426(2), c = 14.426(3) Å, β = 100.06(3)°).